Z
Zhiyong Ma
Researcher at Zhengzhou University
Publications - 23
Citations - 566
Zhiyong Ma is an academic researcher from Zhengzhou University. The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 7, co-authored 23 publications receiving 198 citations.
Papers
More filters
Journal ArticleDOI
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial.
Shun Lu,Jie Wang,Yan Yu,Xinmin Yu,Yanping Hu,Xinghao Ai,Zhiyong Ma,Xingya Li,Wu Zhuang,Yunpeng Liu,Weidong Li,Jiuwei Cui,Dong Wang,Wangjun Liao,Jianying Zhou,Zhehai Wang,Yuping Sun,Xiusong Qiu,Jie Gao,Yuanyuan Bao,Liang Liang,Mengzhao Wang +21 more
TL;DR: Tislelizumab, an anti-programmed cell death protein-1 antibody, was specifically engineered to minimize FcR macrophage binding to abrogate antibody-dependent phagocytosis as discussed by the authors.
Journal ArticleDOI
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
Qing Zhou,Chong-Rui Xu,Ying Cheng,Yunpeng Liu,Gongyan Chen,Jiuwei Cui,Nong Yang,Yong Song,Xiao-Ling Li,Shun Lu,Jianying Zhou,Zhiyong Ma,Shiying Yu,Cheng Huang,Yongqian Shu,Zhen Wang,Jin-Ji Yang,Hai-Yan Tu,Wen-Zhao Zhong,Yi-Long Wu +19 more
TL;DR: In this article, the authors investigated the efficacy and safety of an erlotinib plus bevacizumab regimen in untreated patients with advanced non-small cell lung cancer (NSCLC).
Journal ArticleDOI
CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC
Qing Zhou,Y-L. Wu,Y. Cheng,Y. Liu,Gongyan Chen,Jiuwei Cui,N. Yang,Yuqin Song,Xiao-Ling Li,Shaoyong Lu,Jiaojiao Zhou,Zhiyong Ma,Shu-Yan Yu,Cheng Huang,Y. Shu +14 more
TL;DR: As compared with E alone, B plus E showed superior efficacy with acceptable tolerability and could be a new standard first-line regimen in EGFR mutated NSCLC.
Journal ArticleDOI
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
Yuankai Shi,Xingsheng Hu,Shucai Zhang,Dongqing Lv,Lin Wu,Qitao Yu,Yiping Zhang,Li Liu,Xiang Wang,Ying Cheng,Zhiyong Ma,Hongrui Niu,Dong Wang,Jifeng Feng,Cheng Huang,Chunling Liu,Hui Zhao,Jingzhang Li,Xiaodong Zhang,Yong Jiang,Chuan Gu +20 more
TL;DR: In this article, the efficacy and safety of furmonertinib in patients with EGFR T790M mutated advanced non-small-cell lung cancer (NSCLC) were evaluated by a single-arm open-label, phase 2b study at 46 hospitals across mainland China.
Journal ArticleDOI
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation.
Yuankai Shi,Shucai Zhang,Xingsheng Hu,Jifeng Feng,Zhiyong Ma,Jianying Zhou,Nong Yang,Lin Wu,Wangjun Liao,Dafang Zhong,Xiaohong Han,Ziping Wang,Xiaodong Zhang,Shukui Qin,Kejing Ying,Jian Feng,Jian Fang,Li Liu,Yong Jiang +18 more
TL;DR: Alflutinib was clinically effective with an acceptable toxicity profile in advanced NSCLC patients (including those with CNS metastases) with EGFR T790M mutation and its active metabolite were comparable at steady state.